drugset / Trial / NCT03129698
The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
52 patients with extensive-stage small-cell lung cancer and without progression after completing chemotherapy, will receive apatinib monotherapy as maintenance therapy.
Timeline
- Start
- 2017-04-11
- Primary completion
- 2019-03-01
- Completion
- 2020-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | — |
Indications
No indication recorded.